5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be
Bev’s Story Participant Story Bev Snedden Hunter Valley, NSW When Bev Snedden was diagnosed with non-Hodgkin lymphoma in 2011, her positive outlook on life was put to the test. But the chance to join the TROG 99.03 clinical trial gave Bev the opportunity to be part of the
Cancer Types Lymphoma Cancer The primary aim of the TROG 99.03 trial was to see if, by adding immuno-chemotherapy to the standard treatment of radiotherapy alone, outcomes could be improved for patients with stage I-II low-grade follicular lymphoma. This multi-centre international study, which accrued 150 participants across Australia, New
TROG Publications Over the past 25 years, TROG Cancer Research has recorded 220 publications in national and international journals. View our current list of publications below. Month/Year published TROG Number Acronym Tumour Citation Category Journal 12/01/2026 99.03 Lymphoma Johnstone P, Bressel M, Seymour JF, Juneja S, Ahmad H, MacManus
